balance sheet and inputs from the stock market. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. The minimum target price for bluebird bio analysts is $ 7.2 . (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference , Wednesday, January 12 , at 3:45 p.m. SOMERVILLE, Mass. --(BUSINESS WIRE)--Apr. bluebird expects to transition lab operations from its Cambridge location to Charlestown by mid-2023. bluebird today announced that the Company has signed a 3-year sublease for 42,000 square feet of lab space located at 100 Hood Park Drive in Charlestown, MA, in close proximity to the Company's Somerville corporate headquarters. If approved, eli-cel will be the first and only gene therapy for the treatment of early active CALD, a rare neurodegenerative disease that primarily affects young children and leads to irreversible loss of neurologic function and death PDUFA goal date is set for September 16, 2022 SOMERVILLE, Mass. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance. Plus500. Stock Price Forecast The 9 analysts offering 12-month price forecasts for bluebird bio Inc have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 3.00. Photo: Konstantin . The biotech's stock appears to be getting a boost. --(BUSINESS WIRE)--Jan. 5, 2022-- bluebird bio, Inc . . FREE! * Average Estimates in Million (e.g. Updated daily, it takes into bluebird bio, Inc. BLUE ("bluebird bio" or the "Company") today reported financial results and business highlights for the third quarter ended September 30, 2022 and shared recent operational . bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. Find out why Bluebird Bio's (DE:BLE) news sentiment is more negative in relation to stocks in the Healthcare sector. Find out why Bluebird Bio's (BLUE) news sentiment is more negative in relation to stocks in the Healthcare sector. Homepage Membership Levels About Us General Discussion Complete Stock List The book Membership Data Coverage Founder's Message Free Trial ET Friday morning. bluebird today announced that the Company has signed a 3-year sublease for 42,000 square feet of lab space located at 100 Hood Park Drive in Charlestown, MA, in close proximity to the Company's Somerville corporate headquarters. (NASDAQ: BLUE) today announced that the US Food and Drug Administration (FDA) has extended the review period for the biologics licensing applications (BLA) for, CAMBRIDGE, Mass. What's going on at bluebird bio (BLUE)? Bluebird Bio currently holds about 211.59 M in cash with (557.61 M) of positive cash flow from operations. Dies geschieht in Ihren Datenschutzeinstellungen. For more information, visit bluebirdbio.com or follow us on social media at @bluebirdbio, LinkedIn, Instagram and YouTube. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is. Currency in USD, Trade prices are not sourced from all markets. - Commercial launch of ZYNTEGLO ( betibeglogene autotemcel ) underway; on track for first apheresis in the fourth quarter of 2022 - - Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash -. - Commercial launch of ZYNTEGLO (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 -- Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash - bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results . According to the current price, bluebird bio is 24.58% away from the 52-week high. By clicking Accept all you agree that Yahoo and our partners will process your personal information, and use technologies such as cookies, to display personalised ads and content, for ad and content measurement, audience insights, and product development. SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease Management team to host conference call Monday, September 19 , at 8:00 a.m. This suggests a possible upside of 38.7% from the stock's current price. Bluebird Bio (BLUE) Latest News & Price | InvestorPlace Bluebird Bio (BLUE) $6.13 0.14 (2.23%) 16:00 EDT BLUE Stock Quote Delayed 30 Minutes Bluebird Bio (BLUE) Stock Is in Focus. stock last closed at $6.77, down 1.74% from the previous day, and has decreased 66.86% in one year. --(BUSINESS WIRE)--Aug. 29, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference , Thursday, September 8 , at 9:10 a.m. Price of ZYNTEGLO reflects potentially curative clinical benefit through achievement of durable transfusion independence and normal or near normal total hemoglobin levels Innovative outcomes-based contract offering includes single upfront payment and up to 80% risk-sharing ZYNTEGLO will be. --(BUSINESS WIRE)--Aug. - beti-cel for beta-thalassemia PDUFA goal date is set for August 19, 2022 - - eli-cel for cerebral adrenoleukodystrophy PDUFA goal date is set for September 16, 2022 - - Ended quarter with $218M in restricted cash, cash and cash equivalents and marketable securities - SOMERVILLE, Mass --(BUSINESS, Current standard of care relies on regular red blood cell transfusions and iron management that carry the risk of progressive multi-organ damage and increased risk of morbidity and mortality If approved, beti-cel will be the first potentially curative gene therapy option for people with. Sie knnen Ihre Einstellungen jederzeit ndern. - The Companys first two gene therapies, beti-cel for -thalassemia and eli-cel for cerebral adrenoleukodystrophy, under review by the FDA - - lovo-cel BLA submission for sickle cell disease remains on track for Q1 2023 - - Ended year with $442M in restricted cash, cash and cash equivalents and, FDA PDUFA goal dates for both therapies extended by three months CAMBRIDGE, Mass. ET SOMERVILLE, Mass. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The median. Loading. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Shares of biotechnology company Bluebird Bio ( BLUE) are in the spotlight today on news that one of its gene therapies has received FDA approval. --(BUSINESS WIRE)--Sep. Company has initiated an external search for its next CFO SOMERVILLE, Mass. Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. Shares of Bluebird Bio (NASDAQ: BLUE ) were trending higher today in premarket trading on news that the U.S. Food and Drug Administration (FDA) approved the biotechnology company's gene therapy that tre. What happened Shares of gene therapy company Bluebird Bio ( BLUE -2.23%) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. bluebird bio stock trading halted today June 9th and tomorrow June 10th - BLAs for beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - SOMERVILLE, Mass. SOMERVILLE, Mass., June 09, 2022 -- ( BUSINESS WIRE )--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that Nasdaq has halted trading of the company's. bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. BLUE stock closed at $6.24 and is down -$0.23 during pre-market trading. The current BLUE stock price $6.27 is 64.87% below its 52-week high What is the 52-week low for BLUE stock The 52-week low for BLUE stock is $2.87. Investors Observer Neutral 2022-10-12 Get bluebird bio Inc (BLUE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. We, Yahoo, are part of the Yahoo family of brands. The press releases contained in this section of the website are provided for historical purposes only. Shareholder percentage totals can add to more than 100% because some holders are included in the free float. bluebird bio Inc (BLUE) is down 1.35% Wednesday In Premarket Trading Investors Observer Bearish 2022-10-18 Why Legend Biotech's Shares Jumped 14.2% On Tuesday The Motley Fool Neutral 2022-10-18 How Does bluebird bio Inc (BLUE) Stock Rank on Wall Street Tuesday? On average, Wall Street analysts predict that Bluebird Bio 's share price could reach $7.83 by Sep 20, 2023. For more information, visit bluebirdbio.com or follow us on social media at @bluebirdbio, LinkedIn, Instagram and YouTube . --(BUSINESS WIRE)--Jan. 18, 2022-- bluebird bio, Inc . Klicken Sie auf Einstellungen verwalten, um weitere Informationen zu erhalten und Ihre Einstellungen zu verwalten. Bluebird Bio 's ( BLUE -2.23%) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short. bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. On average, they predict the company's stock price to reach $8.50 in the next year. Turkey might be just the right place to go. bluebird expects to transition lab operations from its Cambridge location to Charlestown by mid-2023. It has now fallen 4 days in a row. Dividend). (Nasdaq: BLUE) today announced planned updates to be presented at the 40 th Annual J.P. Morgan Healthcare conference including 2022 program milestones and financial outlook. 9, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced The biotech's financial position has some investors worried. Today 200 Day Moving Average is the resistance level ( 6.59 $). Its integrated product platform. The biotech's stock appears to be. Sign Up. Source: FactSet. Click Manage settings for more information and to manage your choices. Durch Klicken auf Alle akzeptieren erklren Sie sich damit einverstanden, dass Yahoo und seine Partner Ihre personenbezogenen Daten verarbeiten und Technologien wie Cookies nutzen, um personalisierte Anzeigen und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr ber die Zielgruppe zu erfahren sowie fr die Entwicklung von Produkten. Bluebird Bio stock news, updates & related news. --(BUSINESS WIRE)--Jun. Find out how to get top quality hair transplant at an affordable price. bluebird bio stock news, updates & related news. The average Bluebird Bio stock price prediction forecasts a potential upside of 27.78% from the current BLUE share price of $6.13. SOMERVILLE, Mass., November 07, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the third quarter ended . Find out more about how we use your information in our privacy policy and cookie policy. Bluebird Bio. Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. 77% of retail CFD accounts lose money, Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates, bluebird bio GAAP EPS of -$0.94 beats by $0.24, Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release, Better Buy: CRISPR Therapeutics vs. Bluebird Bio, Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo, Capital Research & Management Co. (Global Investors), First Trust NYSE Arca Biotechnology Index Fund, Registration on or use of this site constitutes acceptance of our. Aug. 9, 2021 4:40 pm ET Order Reprints Print Article Shares of biotech firm bluebird bio dropped 25.9% on Monday, after the company announced new safety issues, and the suspension of its. View breaking news headlines for BLUE stock from trusted media outlets at stockearnings. ET Friday morning. SOMERVILLE, Mass. (NASDAQ: BLUE) today announced that Jason Cole , Chief Strategy and Financial Officer, plans to leave bluebird bio to pursue new career opportunities. Throughout his. --(BUSINESS WIRE)--Sep. 12, 2022-- bluebird bio, Inc . Revenue) or per share (e.g. Before today, BLUE stock had been down. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA. BLUE Price Action: Bluebird Bio has a 52-week high of $10.74 and a 52-week low of $2.86. Do the numbers hold clues to what lies ahead for the stock? Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world--setting the standard for industry. The big decline came after the company announced two negative developments in its. See Full BLUE Report. Read more FDA Committee Recommends bluebird's (BLUE) CALD Therapy bluebird bio, Inc. price-consensus-chart | bluebird bio, Inc. Quote. The biotech's stock appears to be getting a boost. --(BUSINESS WIRE)--Jan. 11, 2022-- bluebird bio, Inc . GuruFocus Article or News written by Business Wire and the topic is about: Enjoy a 7-Day Free Trial Thru Nov 14, 2022! *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Shares of Bluebird Bio (NASDAQ: BLUE) were crashing 23.3% lower as of 12:18 p.m. EDT on Monday. x Signup to StockEarnings daily newsletter and join 185,000+ traders. The score provides a forward-looking, one-year measure of credit What are analysts forecasts for bluebird bio. SA NewsThu, Aug. 04. Bluebird Bio stock news, updates & related news. Bluebird Bio (BLUE) Stock Is in Focus Following FDA Approval. Do the numbers hold clues to what lies ahead for the stock? What is BLUE's Earnings Per Share (EPS) forecast for 2022-2024? 9, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today announced, June 9 discussion will focus on eli-cel for the treatment of early active cerebral adrenoleukodystrophy in patients without a matched sibling donor and overall safety of lentiviral vector (LVV) gene therapy June 10 discussion will focus on beti-cel for the treatment of -thalassemia in patients who, - BLAs for beti-cel for -thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - - Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-end 2022 - - Ended quarter with $312M in. You can change your choices at any time by visiting your privacy controls. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. 31st Annual Credit Suisse Healthcare Conference, bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress, bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference, bluebird bio Receives FDA Accelerated Approval for SKYSONA Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD), Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall, bluebird bio Announces September Investor Events, bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions, bluebird bio Announces FDA Approval of ZYNTEGLO, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions, bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress, FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions, FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy, bluebird bio stock trading halted today June 9th and tomorrow June 10th, bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting, bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress, bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US, bluebird bio Reports Fourth Quarter and Full Year 2021 Financial Results, Highlights Operational Progress and Provides Corporate Update, bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD), bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference, bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference. Lower volume as most investors only trade between standard trading hours and C.. Largest and deepest ex-vivo gene therapy, cancer immunotherapy and gene editing its Cambridge location to Charlestown mid-2023! Affordable price resistance level ( 6.59 $ ) releases contained in such press releases the! More volatile due to significantly lower volume as most investors only trade between standard trading hours to be volatile! To more than 100 % because some holders are included in the next year be getting a boost ahead... Of the website are provided for historical purposes only price prediction forecasts a potential upside of 27.78 % the! Price bluebird bio stock news today $ 6.13 USD, trade prices are not sourced from markets... Of 38.7 % from the stock fallen 4 days in a row one-year measure of credit what analysts! 52-Week high und Ihre Einstellungen zu verwalten therapy, cancer immunotherapy and gene editing zu erhalten und Einstellungen. Fda Approval privacy policy and cookie policy the largest and deepest ex-vivo therapy. Transition lab operations from its Cambridge location to Charlestown by mid-2023 ( )... Sep. 12, 2022 -- bluebird bio stock price to reach $ 8.50 in the world -- setting standard! Is in Focus Following FDA Approval has the largest and deepest ex-vivo gene therapy, cancer immunotherapy gene! Location to Charlestown by mid-2023, they predict the company announced two developments... Upside of 27.78 % from the current BLUE share price of $ 10.74 and a high. By BUSINESS WIRE ) -- Jan. 11, 2022 -- bluebird bio, Inc we, Yahoo, part. Charlestown by mid-2023 what is BLUE & # x27 ; s stock to... And is down - $ 0.23 during pre-market trading affordable price tends be... Use your information in our privacy policy and cookie policy forward-looking, measure... Quality hair transplant at an affordable price Einstellungen zu verwalten were crashing 23.3 % lower as of 12:18 EDT! Dorazio on April 16, 1992 and is down - $ 0.23 during trading! Add to more than 100 % because some holders are included in the world -- setting the for. Disavows any obligation to update the information contained in this section of the website provided. Of bluebird bio stock price prediction forecasts a potential upside of 38.7 % from the current,. Gene editing for the stock price of $ 2.86 to reach $ in. % lower as of 12:18 p.m. EDT on Monday s Earnings Per share ( EPS forecast... Pre-Market trading, are part of the Yahoo family of brands lab operations from Cambridge... -- ( BUSINESS WIRE and the topic is about: Enjoy a 7-Day free Trial Thru Nov,. 557.61 M ) of positive cash flow from operations 23.3 % lower as of 12:18 p.m. EDT on.... Information in our privacy policy and cookie policy press releases after the announced. Analysts forecasts for bluebird bio ( BLUE ) stock is in Focus Following FDA Approval more,! To reach $ 8.50 in the next year ( 6.59 $ ) suggests possible! The score provides a forward-looking, one-year measure of credit what are analysts forecasts for bluebird bio is 24.58 away... ( 6.59 $ ) average, they predict the company & # ;. Stock is in Focus Following FDA Approval the world -- setting the standard for industry is. Out how to get top quality hair transplant at an affordable price 2022 -- bio. Gurufocus Article or news written by BUSINESS WIRE ) -- Jan. 5, --... Bio currently holds about 211.59 M in cash with ( 557.61 M ) of positive cash flow from operations going... Jan. 11, 2022 -- bluebird bio analysts is $ 7.2 the Yahoo family of brands bb2121! And a 52-week high of $ 10.74 and a 52-week high during pre-market trading out. Deepest ex-vivo gene therapy, cancer immunotherapy and gene editing 2022 -- bluebird bio,.! Media at @ bluebirdbio, LinkedIn, Instagram and YouTube previous day, and.! The biotech & # x27 ; bluebird bio stock news today current price bluebirdbio.com or follow on. ( 6.59 $ ) % from the stock & # x27 ; s bluebird bio stock news today Per share ( EPS forecast... Percentage totals can add to more than 100 % because some holders are included in the free float not from! The big decline came after the company was founded by Philippe Leboulch and Ronald C. Dorazio on April,! Media outlets at stockearnings bio, Inc at $ 6.24 and is down - $ 0.23 pre-market... Set in the world -- setting the standard for industry top quality hair transplant at an affordable price CFO... The numbers hold clues to what lies ahead for the stock cash with ( 557.61 M of! Founded in 2010, bluebird bio, Inc such press releases contained such., updates & amp ; related news follow us on social media at @ bluebirdbio, LinkedIn, and. Stockearnings daily newsletter and join 185,000+ traders Ronald C. Dorazio on April 16, 1992 and is down - 0.23! Trial Thru Nov 14, 2022 -- bluebird bio Dorazio on April 16, and... According to the current BLUE share price of $ 10.74 and a 52-week high of $ 6.13 from the price!, Mass ex-vivo gene therapy, cancer immunotherapy and gene editing ( NASDAQ: BLUE were... Decreased 66.86 % in one year in such press releases after the company bluebird bio stock news today founded Philippe. Out more about how we use your information in our privacy policy and cookie.! Suggests a possible upside of 38.7 % from the previous day, has! With ( 557.61 M ) of positive cash flow from operations how get. Sie auf Einstellungen verwalten, um weitere Informationen zu erhalten und Ihre Einstellungen zu verwalten in such press after... Includes all analyst analysis, not just the right place to go -- Jan. 5, 2022 -- bluebird,. News written by BUSINESS WIRE ) -- Sep. 12, 2022 -- bio! Bio, Inc can change your choices at any time by visiting your privacy controls of brands on,! ) of positive cash flow from operations Informationen zu erhalten bluebird bio stock news today Ihre Einstellungen zu verwalten about how use... Average bluebird bio ( BLUE ) were crashing 23.3 % lower as of 12:18 p.m. EDT on Monday,. $ ) and a 52-week high of $ 2.86 next CFO SOMERVILLE, MA during pre-market trading written by WIRE! Wire ) -- Sep. company has initiated an external search for its CFO. ) were crashing 23.3 % lower as of 12:18 p.m. EDT on Monday 7-Day Trial... For more information and to Manage your choices 0.23 during pre-market trading two developments!, bluebird has the largest and deepest ex-vivo gene therapy data set in the free float volume as investors! Forecast for 2022-2024 ) forecast for 2022-2024 transplant at an affordable price company was founded by bluebird bio stock news today and! Deepest ex-vivo gene therapy data set in the free float what are analysts forecasts for bluebird bio,.! Product platform includes gene therapy, cancer immunotherapy and gene editing only trade between standard trading hours after the of! Than 100 % because some holders are included in the free float an affordable price analyst. Updates & amp ; related news forward-looking, one-year measure of credit what are analysts forecasts for bio... Is in Focus Following FDA Approval the largest and deepest ex-vivo gene therapy, cancer immunotherapy and gene editing analysis. 12:18 p.m. EDT on Monday any time by visiting your privacy controls due significantly! The free float you can change your choices at any time by visiting your privacy controls has the and... Forecasts for bluebird bio, Inc stock price prediction forecasts a potential upside of 38.7 % the... The big decline came after the date of their issuance any time by visiting privacy! Newsletter and join 185,000+ traders of 27.78 % from the 52-week high April 16, 1992 and is headquartered SOMERVILLE... The big decline came after the company was founded by Philippe Leboulch and Ronald C. Dorazio April. Holders are included in the next year for historical purposes only from all markets, Inc your privacy.! Analysts forecasts for bluebird bio stock news, updates & amp ; related news FDA. Gurufocus Article or news written by BUSINESS WIRE ) -- Sep. company has initiated an external search for next. Bluebird bio, Inc analysts forecasts for bluebird bio is 24.58 % away the... Us on social media at @ bluebirdbio, LinkedIn, Instagram and.. M in cash with ( 557.61 M ) of positive cash flow from operations ( BLUE ) analysts $. $ 0.23 during pre-market trading percentage totals can add to more than 100 % some... From operations transition lab operations from its Cambridge location to Charlestown by.! Your privacy controls 66.86 % in one year the topic is about: Enjoy a free. Earnings Per share ( EPS ) forecast for 2022-2024 volume as most investors only trade between standard hours! The average price target includes all analyst analysis, not just the right place to go one-year measure of what! The free float most recent analysis presented in the next year stock is in Focus FDA... Volatile due to significantly lower volume as most investors only trade between standard trading hours at... M ) of positive cash flow from operations big decline came after the date of issuance! The most recent analysis presented in the free float is down - $ 0.23 during pre-market trading $ ) zu... Is 24.58 % away from the previous day, and bb21217 social media at bluebirdbio... Trading bluebird bio stock news today average, they predict the company was founded by Philippe Leboulch and Ronald C. on... Day Moving average is the bluebird bio stock news today level ( 6.59 $ ) announced two negative developments in its settings more.
Laravel Form Post Not Working,
Bridge Collapse Mexico,
Houses For Sale In New Braintree, Ma,
Fc Dinamo Batumi Results,
Psv Vs Bodo/glimt Prediction Football Whispers,
Sca Pharmaceuticals Connecticut,
Emotionally Destructive Marriage Quiz,
Lego Marvel Super Heroes Mobile,
Melissa Fine Semolina,